Aceneuramic Acid

Summary

Aceneuramic Acid (CHEMBL2105945) is a phase-3 clinical-stage small molecule (ATC M09AX05).

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: M09AX05
• Chemistry: 309.27 Da · C11H19NO9

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2105945
Name	Aceneuramic Acid
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	14017587
ChEBI	CHEBI:173082
ATC	M09AX05
Molecular formula	C11H19NO9
Molecular weight	309.27
InChIKey	KBGAYAKRZNYFFG-BOHATCBPSA-N

SMILES: CC(=O)N[C@H]([C@H](CC(=O)C(=O)O)O)[C@H]([C@@H]([C@@H](CO)O)O)O

IUPAC name: (4S,5R,6R,7S,8R)-5-acetamido-4,6,7,8,9-pentahydroxy-2-oxononanoic acid

ChEBI definition: An N-acetylneuraminic acid that is keto-neuraminic acid in which one of the hydrogens of the amino group is replaced by an acetyl group.

Also known as: Aceneuramic acid, Acide aceneuramique, Acido aceneuramico, UX001, ACENEURAMIC ACID, SID144205940

Patent coverage: 23,538 distinct patent families (76,044 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).